News

PGEC

IPO Report: Fate Therapeutics (FATE)

Francis Gaskins | Equities.com |

Fate Therapeutics ($FATE) is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including


Humanity. 2.0 - Opening Address at the Vatican

The opening address was delivered by Rev. Philip Larrey, Chairman of. Humanity 2.0, and Matthew. Sanders, CEO & Founder of Humanity 2.0.


Events

Sohn Investment Conference

Wall Street’s best and brightest investors participate in this unique, “must attend” event to share their expertise with an audience of more than 3,000 people, comprised of portfolio managers, asset…

Learn more